Sanjivani Paranteral Ltd

Sanjivani Paranteral Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, raising questions about its price attractiveness amid a volatile market backdrop. Despite a recent surge in share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical and peer averages suggest caution for investors.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 29 July 2026. This revision reflects a notable improvement in valuation metrics alongside a mixed financial trend and technical outlook. Despite recent quarterly setbacks, the company’s fair valuation and operational efficiency have prompted a more favourable stance from analysts.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 28 July 2026. This revision reflects a combination of deteriorating financial trends, expensive valuation metrics, weakening technical indicators, and a reassessment of the company’s overall quality. The downgrade comes despite a recent sharp rally in the stock price, which surged 13.65% on the day following the announcement.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade to Strong Sell. Despite a recent surge in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have moved into expensive territory, raising questions about its price attractiveness relative to historical and peer benchmarks.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Sanjivani Paranteral Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The revision follows a detailed reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, highlighting both the company’s strengths and areas of concern within the Pharmaceuticals & Biotechnology sector.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 July 2026. This revision reflects deteriorating financial performance, bearish technical indicators, and valuation concerns, signalling heightened risk for investors amid a challenging market environment.

Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO, with this rating last updated on 22 June 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 04 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 22 June 2026. This change reflects a nuanced shift in the company’s technical outlook amid ongoing financial headwinds and valuation considerations. While the company’s recent quarterly results remain subdued, improvements in technical indicators and a fair valuation relative to peers have contributed to the revised stance.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 15 June 2026. This shift reflects a reassessment across key parameters including valuation, financial trends, quality metrics, and technical indicators, signalling heightened caution for investors amid deteriorating fundamentals and market underperformance.

Sanjivani Paranteral Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a significant improvement in valuation metrics despite ongoing financial challenges. The pharmaceutical micro-cap’s recent performance and fundamental parameters have been carefully analysed, revealing a complex picture of valuation attractiveness counterbalanced by deteriorating quarterly financial results and subdued market returns.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating. Despite recent share price declines, the company’s improved price-to-earnings and price-to-book ratios relative to peers and historical averages suggest a compelling entry point for discerning investors.

Sanjivani Paranteral Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 02 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Sanjivani Paranteral Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, a shift in valuation metrics, and weakening financial performance, signalling caution for investors in this micro-cap pharmaceutical player.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change comes amid significant price fluctuations and a deteriorating market sentiment, reflected in its recent downgrade to a Strong Sell rating by MarketsMOJO. Investors are now reassessing the stock’s price attractiveness in comparison to its historical averages and peer group benchmarks.

A sharp decline has pushed Sanjivani Paranteral Ltd to a fresh 52-week low of Rs 126 on 21 May 2026, marking a 41.44% drop over the past year, significantly underperforming the Sensex's 7.27% decline during the same period.